Successful clinical response to irinotecan in desmoplastic round blue cell tumor

Medical and Pediatric Oncology

Volumn 33, Issue 5, 1999, Pages 500-503

  Rosoff, Philip M ^a   Bayliff, Sherry ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Desmoplastic round blue cell tumor; Irinotecan

Indexed keywords

IRINOTECAN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; DESMOPLASTIC SMALL ROUND CELL TUMOR; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ABDOMINAL NEOPLASMS; ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DESMIN; FEMALE; HUMANS; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032726374     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199911)33:5<500::AID-MPO12>3.0.CO;2-X     Document Type: Article

References (27)

1. Gerald WL, Miller HK, Battifora H, et al. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals [see comments]. Am J Surg Pathol 1991;15: 499-513.
2. Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol 1998;16:3028-3036.
3. Cummings OW, Ulbright TM, Young RH, et al. Desmoplastic small round cell tumors of the paratesticular region. A report of six cases. Am J Surg Pathol 1997;21:219-225.
4. Frappaz D, Bouffet E, Dolbeau D, et al. Desmoplastic small round cell tumors of the abdomen. Cancer 1994;73:1753-1756.
5. Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996;14:1526-1531.
6. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round blue cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999; 17:180-190.
7. Mazuryk M, Paterson AH, Temple W, et al. Benefit of aggressive multimodality therapy with autologous stem cell support for intra-abdominal desmoplastic small round cell tumor. Bone Marrow Transplant 1998;21:961-963.
8. Schwarz RE, Gerald WL, Kushner BH, et al. Desmoplastic small round cell tumors: prognostic indicators and results of surgical management. Ann Surg Oncol 1998;5:416-422.
9. Kushner BH, Heller G, Cheung NK, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998;16:3016-3020.
10. Abang AM. The clinical pharmacology of topoisomerase I inhibi tors. Semin Hematol 1998;35:13-21.
11. O'Leary JJ, Shapiro RL, Ren CJ, et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan. and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999;5:181-187.
12. Iyer L, Ratain MJ. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 1998;42:S31-S43.
13. Choi SH, Tsuchida Y, Yang HW. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Lett 1998;124:15-21.
14. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-2-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethy1-10-hydroxycamptothecin. Cancer Res 1993;53:2823-2829.
15. Komuro H, Li P, Tsuchida Y, et al. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 1994;23:487-492.
16. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-431.
17. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts, Br J Cancer 1996;74:537-545.
18. Vassal G, Pondarre C, Cappelli C, et al. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur J Cancer 1997; 33:2011-2015.
19. Vassal G, Pondarre C, Boland I, et al. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 1998;80:271-280.
20. Benson AB 3rd. Therapy for advanced colorectal cancer. Semin Oncol 1998;25:2-11.
21. Enzinger PC, Ilson DH, Saltz LB, et al. Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology 1998;12:110-113.
22. Kobayashi K, Shinbara A, Kamimura M. et al. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother Pharmacol 1998;2:53-58.
23. Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998;16:3329-3334.
24. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998;25:39-46.
25. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
26. Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 1998; 16:3858-3865.
27. Ueoka H, Tabata M, Kiura K, et al. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 1999;79:984-990.